Long-term prophylactic agents to lower the attack rate of acute HAE or to shorten the episodes include plasma-derived C1-INH, a monoclonal antibody targeting kallikrein (lanadelumab), and small molecular weight kallikrein inhibitors (berotralstat and avoralstat) given orally [41,42,43,44]. Here, KLK4 is linked to hereditary angioedema.